Orchard Therapeutics (NASDAQ: ORTX)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-03 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.260 | -0.350 | -0.0900 | ||||
REV | 3.960M | 5.524M | 1.564M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Orchard Therapeutics (NASDAQ: ORTX) through any online brokerage.
Other companies in Orchard Therapeutics’s space includes: Alzamend Neuro (NASDAQ:ALZN), Galectin Therapeutics (NASDAQ:GALT), 89bio (NASDAQ:ETNB), Bolt Biotherapeutics (NASDAQ:BOLT) and Gemini Therapeutics (NASDAQ:GMTX).
The latest price target for Orchard Therapeutics (NASDAQ: ORTX) was reported by Barclays on Friday, May 13, 2022. The analyst firm set a price target for 4.00 expecting ORTX to rise to within 12 months (a possible 601.75% upside). 6 analyst firms have reported ratings in the last year.
The stock price for Orchard Therapeutics (NASDAQ: ORTX) is $0.57 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Orchard Therapeutics.
Orchard Therapeutics’s Q2 earnings are confirmed for Wednesday, August 3, 2022.
There is no upcoming split for Orchard Therapeutics.
Orchard Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.